Background: Cannabis withdrawal syndrome (CWS) is characterized by irritability, sleep disorders, and physical discomfort that typically peaks within 7 days of cessation. Case: A patient with a 30-year history of heavy cannabis developed prolonged symptoms of CWS that peaked at greater than 40 days after cessation, who was successfully managed with dexmedetomidine. Discussion: This case report documents an unusual case of significantly delayed CWS peak in symptoms, as well as the novel use of dexmedetomidine for inpatient management of CWS.
CoxEJMaharaoNPatilea-VranaG, et al. A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics. Pharmacol Ther. 2019;201:25-38. doi:10.1016/j.pharmthera.2019.05.001.
6.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association, 2013.
BabsonKASottileJMorabitoD.Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017;19(4):23. doi:10.1007/s11920-017-0775-9 SLEEP
9.
BudneyAJHughesJRMooreBAVandreyR.Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004;161(11):1967-1977. doi:10.1176/appi.ajp.161.11.1967.
10.
HesseMThylstrupB.Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers. BMC Psychiatry. 2013;13(1):1. doi:10.1186/1471-244X-13-258.
11.
AllsopDJCopelandJLintzerisN, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: A randomized clinical trial. JAMA Psychiatry. 2014;71(3):281-291. doi:10.1001/jamapsychiatry.2013.3947.
12.
WerneckMAKortasGTde AndradeAGCastaldelli-MaiaJM.A systematic review of the efficacy of cannabinoid agonist replacement therapy for cannabis withdrawal symptoms. CNS Drugs. 2018;32(12):1113-1129. doi:10.1007/s40263-018-0577-6.
13.
BrezingCALevinFR.The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology. 2018;43(1):173-194. doi:10.1038/npp.2017.212.
LeikinJBAmusinaO.Use of dexmedetomidine to treat delirium primarily caused by cannabis. Am J Emerg Med. 2017;35(3):524e1-524e2. doi:10.1016/j.ajem.2016.10.027.
CiprianiFMancinoAPulitanòSMPiastraMContiG.A cannabinoid-intoxicated child treated with dexmedetomidine: a case report. J Med Case Rep. 2015;9(1):2-5. doi:10.1186/s13256-015-0636-2.
